BioVie Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BIVI research report →
About the company
BioVie Inc. is a clinical-stage biotechnology firm primarily dedicated to the discovery, development, and commercialization of innovative drug treatments across the United States. The company's developmental portfolio includes BIV201, a therapeutic agent that has successfully completed its Phase IIa clinical trial for addressing ascites resulting from chronic liver cirrhosis.
- CEO
- Cuong Viet Do
- IPO
- 2020
- Employees
- 14
- HQ
- Carson City, NV, US
Price Chart
- Market Cap
- $14.71M
- P/E
- -0.74
- P/S
- 0.00
- P/B
- 0.94
- EV/EBITDA
- -0.10
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -101.09%
- ROIC
- -129.50%
- Revenue
- $0 · 0.00%
- Net Income
- $-17,542,120 · 45.39%
- EPS
- $-12.12 · 83.41%
- Op Income
- $-18,066,200
- FCF YoY
- 31.92%
- 52W High
- $9.56
- 52W Low
- $1.06
- 50D MA
- $1.62
- 200D MA
- $1.52
- Beta
- 0.57
- Avg Volume
- 124.42K
Get TickerSpark's AI analysis on BIVI
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Jan 5, 26 | Palumbo Joseph M | other | 132,000 |
| Jan 5, 26 | KIM JOANNE WENDY | other | 110,100 |
| Jan 5, 26 | ROGICH SIGMUND | other | 141,100 |
| Jan 5, 26 | ROGICH SIGMUND | other | 70,000 |
| Jan 5, 26 | DO CUONG V | other | 665,300 |
| Jan 5, 26 | Sherman Michael Edward | other | 341,100 |
| Jan 5, 26 | Sherman Michael Edward | other | 80,000 |
| Jan 5, 26 | Farag Kameel D. | other | 57,500 |
| Jan 5, 26 | Chappell Amy Suzon | other | 57,500 |
| Jan 5, 26 | Lang James Paul | other | 330,500 |
Our BIVI coverage
Recent articles, reports, and earnings notes.
No research on BIVI yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BIVI report →Similar companies
Peers in the same neighborhood.